Disclosure under Chapter 9, Section 10 of the Securities Markets Act (Teemu Suna)
Nightingale Health Plc
Company release
18 June 2024 at 5:05 p.m. (EEST)
Nightingale Health Plc (“Nightingale Health”) has received a notification on 18 June 2024 according to Chapter 9, Section 5 of the Finnish Securities Markets Act, stating that Teemu Suna’s votes exceed 10 % of all votes in Nightingale Health. Teemu Suna’s votes exceeded the notification threshold before April 19, 2024.
The notification of exceeding the voting right threshold is retroactive because an amendment to the Securities Markets Act entered into force on 19 April 2024, according to which the flagging obligation shall also apply to shareholders and persons comparable to shareholders of companies listed on the Nasdaq First North Growth Market Finland. In case a proportion of holdings or votes is at least five percent on 19 April 2024 when the amendment entered into force, a flagging notification shall be made within two months from the commencement of the amendment.
The flagging has been made in accordance with the transitional provisions applicable in connection with the amendment of the law and concerns the holdings in force at the time of the entry into force of the amendment on April 19, 2024.
Total positions of person subject to the notification obligations:
|
|
% of shares and voting rights |
% of shares and voting rights through financial instruments |
Total of both in % |
Total number of shares and voting rights of issuer |
|
Resulting situation on the date on which threshold was reached |
Less than 5% of shares 10.78% of voting rights |
- |
Less than 5% of shares 10.78% of voting rights |
60,918,459 shares 245,092,975 voting rights |
Notified details of the resulting situation on the date on which the threshold was crossed or reached:
|
A: Shares and voting rights |
||||
|
Class/type of shares ISIN code |
Number of shares and voting rights |
% of shares and voting rights |
||
|
Direct(SMA 9:5) |
Indirect(SMA 9:6 ja 9:7) |
Direct(SMA 9:5) |
Indirect(SMA 9:6 ja 9:7) |
|
|
HEALTH FI4000490875 |
31,237 |
- |
0.05% of shares 0.01% of voting rights |
- |
|
HEALTHA FI4000490867 |
2,637,964 |
- |
4.33% of shares 10.76% of voting rights |
- |
|
SUBTOTAL A |
2,669,201 |
- |
4.38% of shares 10.78% of voting rights |
- |
For further information, please contact:
Teemu Suna, CEO
ir@nightingalehealth.com
Certified advisor:
Oaklins Merasco Ltd, tel. +358 9 6129 670
About Nightingale Health
Nightingale Health’s mission is to build sustainable healthcare and reduce health inequalities. Nightingale Health has developed the world’s most advanced health check that provides risk detection for multiple chronic diseases from a single blood sample. Nightingale’s Health Check can be scaled to entire populations at a low cost, and it can replace many of the current clinical risk assessments. Detecting disease risks on a population level allows for the effective targeting and tracking of health interventions, and better prevention of the onset of chronic diseases. With every sample we help to create a healthier world.
Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The company’s technology is being used in many of the world’s leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. The company’s Series B shares are listed on the First North Growth Market Finland marketplace. Read more: https://nightingalehealth.com
Tags:
